Clinical Trial Results:
A randomized, double-blinded, placebo-controlled trial that evaluates the effect of empagliflozin on oxidative stress in patients with type 2 diabetes
Summary
|
|
EudraCT number |
2016-000370-38 |
Trial protocol |
DK |
Global end of trial date |
22 Jan 2020
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
04 Feb 2021
|
First version publication date |
04 Feb 2021
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
2016-100
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT02890745 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Department of Clinical Pharmacology, Bispebjerg-Frederiksberg Hospital - Rigshospitalet, Q7642
|
||
Sponsor organisation address |
Blegdamsvej 9, Copenhagen, Denmark,
|
||
Public contact |
Henrik Enghusen Poulsen, Department of Clinical Pharmacology,
Bispebjerg-Frederiksberg Hospital,
Denmark, +45 35457695, henrik.enghusen.poulsen.01@regionh.dk
|
||
Scientific contact |
Henrik Enghusen Poulsen, Department of Clinical Pharmacology,
Bispebjerg-Frederiksberg Hospital,
Denmark, +45 35457695, henrik.enghusen.poulsen.01@regionh.dk
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
01 Nov 2020
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
22 Jan 2020
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
22 Jan 2020
|
||
Was the trial ended prematurely? |
Yes
|
||
General information about the trial
|
|||
Main objective of the trial |
Urinary excretion rates of 8-oxo-7,8-dihydroguanosine (8-oxoGuo) and 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodG) before and after treatment with empagliflozin compared to placebo treatment in addition to standard care in patients with type 2 diabetes
|
||
Protection of trial subjects |
All data was stored in accordance with the Danish Law of data protection
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
23 Nov 2016
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Denmark: 35
|
||
Worldwide total number of subjects |
35
|
||
EEA total number of subjects |
35
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
18
|
||
From 65 to 84 years |
17
|
||
85 years and over |
0
|
|
||||||||||
Recruitment
|
||||||||||
Recruitment details |
Recruitment were done in relation to patients outpatient consultation at Gentofte Hospital and Bispebjerg Hospital as well as throug advertisements at public availiable material. | |||||||||
Pre-assignment
|
||||||||||
Screening details |
A screening visit is performed prior to enrollment in the study to ensure elibility of study criteria with an physical examination and disease and life style history | |||||||||
Period 1
|
||||||||||
Period 1 title |
Overall trial (overall period)
|
|||||||||
Is this the baseline period? |
Yes | |||||||||
Allocation method |
Randomised - controlled
|
|||||||||
Blinding used |
Double blind | |||||||||
Roles blinded |
Subject, Investigator, Monitor, Data analyst, Assessor | |||||||||
Arms
|
||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||
Arm title
|
Intervention | |||||||||
Arm description |
Active arm. Empagliflozin 25 mg, once daily for 14 days | |||||||||
Arm type |
Experimental | |||||||||
Investigational medicinal product name |
empagliflozin
|
|||||||||
Investigational medicinal product code |
||||||||||
Other name |
||||||||||
Pharmaceutical forms |
Tablet
|
|||||||||
Routes of administration |
Oral use
|
|||||||||
Dosage and administration details |
25 mg, tablet, oral use
|
|||||||||
Arm title
|
Placebo | |||||||||
Arm description |
Placebo | |||||||||
Arm type |
Placebo | |||||||||
Investigational medicinal product name |
Placebo
|
|||||||||
Investigational medicinal product code |
||||||||||
Other name |
||||||||||
Pharmaceutical forms |
Tablet
|
|||||||||
Routes of administration |
Oral use
|
|||||||||
Dosage and administration details |
Placebo, tablet, oral use
|
|||||||||
|
||||||||||
Notes [1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same. Justification: A total number of 35 participants were enrolled in the study. However, 4 participants chose to withdrew before getting trial medicine, and were thus not included in the baseline information. |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Overall trial
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Intervention
|
||
Reporting group description |
Active arm. Empagliflozin 25 mg, once daily for 14 days | ||
Reporting group title |
Placebo
|
||
Reporting group description |
Placebo |
|
|||||||||||||
End point title |
Changes in urinary excretion of 8-oxo-7,8-dihydroguanosine | ||||||||||||
End point description |
|||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Changes from baseline to end of study
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Between group effects 8-oxo-7,8-dihydroguanosine | ||||||||||||
Comparison groups |
Placebo v Intervention
|
||||||||||||
Number of subjects included in analysis |
31
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
equivalence | ||||||||||||
P-value |
= 0.66 | ||||||||||||
Method |
t-test, 2-sided | ||||||||||||
Parameter type |
Mean difference (final values) | ||||||||||||
Point estimate |
1.3
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-4.2 | ||||||||||||
upper limit |
4.8 |
|
|||||||||||||
End point title |
Changes in urinary excretion of 8-oxo-7,8-dihydro-2'-deoxyguanosine | ||||||||||||
End point description |
|||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Changes from baseline to end of study
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Between group effects 8-oxo-7,8-dihydro-2'-deoxygu | ||||||||||||
Comparison groups |
Intervention v Placebo
|
||||||||||||
Number of subjects included in analysis |
31
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
equivalence | ||||||||||||
P-value |
= 0.89 | ||||||||||||
Method |
t-test, 2-sided | ||||||||||||
Parameter type |
Mean difference (final values) | ||||||||||||
Point estimate |
0.3
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-4.2 | ||||||||||||
upper limit |
4.8 |
|
|||||||||||||
End point title |
Changes in plasma concentration of malondialdehyde | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Changes from baseline to end of study
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Between group effect malondialdehyde | ||||||||||||
Comparison groups |
Intervention v Placebo
|
||||||||||||
Number of subjects included in analysis |
31
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
equivalence | ||||||||||||
P-value |
= 0.33 | ||||||||||||
Method |
t-test, 2-sided | ||||||||||||
Parameter type |
Mean difference (final values) | ||||||||||||
Point estimate |
-0.22
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-0.66 | ||||||||||||
upper limit |
0.23 |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
During the study period (14 days) and one week afterwards
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
Daily text messages and at the end of study. If any occured the week following the study, participants contacted the investiagator
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
23.1
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Intervention group
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Empagliflozin 25 mg, once daily for 14 days | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Placebo for 14 days | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 1% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
The project did not include 34 participants that succesfully completed the study. 35 partipants were enrolled, however, 4 participants withdrew before starting trial medicine. Thus, 31 participants succesfully completed the study. |